NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates with Dr. Daniel Carter to Enter Race to Develop Potential COVID-19 Vaccine

May 6, 2020 11:04:50

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID-19 vaccine with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter. According to the update, the groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein), which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1), an iron storage protein found in all living things. NIH is currently exploiting the ferritin platform in its exploration of the universal flu vaccine which completed phase I clinical trials earlier this year and is currently recruiting for a second phase 1 trial on a modified version of the ferritin self-assembly universal vaccine (2,3). POAI has entered into an agreement with Dr. Carter under which it is licensing this technology, subject to certain conditions. According to Dr. Carter, principal inventor of the ferritin self-assembling nanoparticle platform (1), now widely applied by many, including NIH, to other applications and principal inventor of the new NSP10 approach, “NSP10 is a ‘game changer’ vaccine platform with significant advantages. These game changer properties have also been validated with SARS-CoV-2 vaccine candidates – resulting in extraordinary animal titers against the coronavirus spike protein which is required for viral infectivity – all with a simple injection of small quantities of DNA.”

To view the full press release, visit

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other) that contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled with a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform Kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient-specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, visit the company’s website at

  1. C. Carter and C. Li, “Genetically Engineered Ferritin as a Vehicle for Vaccine Production, Biomaterials, Oxygen Transport, and Therapeutic Delivery, issued in Germany, France, United Kingdom, China and Canada, US Patent No. 7,097,841(2006)
  2. Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens with an Influenza DNA Vaccine in Healthy Adults:
  3. Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine, VRCFLUNPF099-00-VP, in Healthy Adults:

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.